Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage IIIA-N2 NSCLC
NCT03749213Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Feb 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Primary endpoint: Objective Response Rate at 8 weeks. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03749213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03749213.